Specific site methylation in the 5′-flanking region of CYP1A2 -: Interindividual differences in human livers

被引:39
作者
Hammons, GJ [1 ]
Yan-Sanders, Y [1 ]
Jin, B [1 ]
Blann, E [1 ]
Kadlubar, FF [1 ]
Lyn-Cook, BD [1 ]
机构
[1] Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA
关键词
CpG methylation; epigenetic regulation; CYP1A2; hypermethylation;
D O I
10.1016/S0024-3205(01)01175-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Human cytochrome P450 1A2 (CYP1A2) is involved in the metabolism of a large number of common drugs and is responsible for the metabolic activation of numerous promutagens and procarcinogens. Large interindividual differences exist in the expression of this enzyme. This variability has important implications for drug efficacy and cancer susceptibility. In this sudy, the methylation status of the CCGG site (bp -2759) located adjacent to an AP-1 site in the 5 ' -flanking region of the CYP1A2 gene was assessed in liver samples from a pool of 55 human donors. DNA methylation is an important epigenetic mechanism controlling gene expression and may be one of the molecular mechanisms underlying the interindividual variation. Analysis was conducted using Hpa II digestion and PCR. Results showed that individual samples varied in the methylation status at this site. The site was found to be hypermethylated in similar to 60% of the samples. To compare methylation status with level of CYP1A2 expression, results were analyzed by median test. In 44% of the samples with expression levels above the median the CCGG site was hypermethylated. However, for those samples with levels below the median hypermethylation of the site was found in 73% of the samples. The difference was statistically significant (p <0.05), These findings indicate that CpG methylation may be involved in controlling the expression of CYP1A2, with hypermethylation reducing expression. Moreover, this approach can be useful in assessing the role of site-specific DNA methylation in interindividual variation of CYP1A2. Analysis of other CpG sites in potentially important regulatory elements of the CYP1A2 gene will continue, (C) 2001 Elsevier Science. All rights reserved.
引用
收藏
页码:839 / 845
页数:7
相关论文
共 34 条
[1]
IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]
BEDNARIK DP, 1991, NEW BIOL, V3, P969
[3]
TISSUE-SPECIFIC EXPRESSION AND METHYLATION OF THE HUMAN CYP2E1 GENE [J].
BOTTO, F ;
SEREE, E ;
ELKHYARI, S ;
DESOUSA, G ;
MASSACRIER, A ;
PLACIDI, M ;
CAU, P ;
PELLET, W ;
RAHMANI, R ;
BARRA, Y .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (06) :1095-1103
[4]
DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[5]
CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [J].
Carrillo, JA ;
Benitez, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (06) :605-608
[6]
Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].
Chida, M ;
Yokoi, T ;
Fukui, T ;
Kinoshita, M ;
Yokota, J ;
Kamataki, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902
[7]
CHUNG I, 1995, MOL PHARMACOL, V47, P677
[8]
Daniel W., 1978, APPL NONPARAMETRIC S
[9]
Role of the ras-MAPK signaling pathway in the DNA methyltransferase response to DNA hypomethylation [J].
Deng, C ;
Yang, J ;
Scott, J ;
Hanash, S ;
Richardson, BC .
BIOLOGICAL CHEMISTRY, 1998, 379 (8-9) :1113-1120
[10]
EATON DL, 1995, PHARMACOGENETICS, V5, P59